-
平臺編號：bio-49427
-
國際編號：ATCC VR-2028
-
拉丁屬名： Vaccinia virus
-
規(guī)格：frozen
-
用途：ATCC原裝進(jìn)口
-
服務(wù)費用：
加載中…… - 訂購
-
注意事項：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準(zhǔn)）
Vaccinia virus
ATCC? Number:VR-2028?
Classification: Poxviridae, Orthopoxvirus
Agent: Vaccinia virus
Strain: vP-5 [recombinant Vaccinia virus]
Depositors: E Paoletti
Biosafety Level:2
Shipped: frozen
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Host Organism : HeLa cells (ATCCCCL-2); CV-1 cells (ATCCCCL-70)
Effect : Yes, in vitro effects: Cytopathic effects in tissue culture
Comments : A recombinant virus consisting of an HSV-TK insert in vaccinia vTK-11. The recombinant does not express thymidine kinase. A recombinant virus consisting of an HSV-TK insert in vaccinia vTK-11. The recombinant does not express thymidine kinase. This clone does not express the inserted herpes thymidine kinase gene. [13123] A BamHI fragment coding for herpes TK was cloned into the BamHI site of the vaccinia HindIII F-fragment. This construct was then cloned into VTK-11 by in vivo recombination. [13123]
References : 13123: Paoletti E, Panicali D. Modified vaccinia virus. US Patent 4,603,112 dated Jul 29 1986 13130: Paoletti E, Panicali D. Method for immunizing animals with synthetically modified vaccinia virus. US Patent 4,722,848 dated Feb 2 1988 13139: Panicali D, et al. Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus. J. Virol. 37: 1000-1010, 1981. PubMed: 6262520
Classification: Poxviridae, Orthopoxvirus
Agent: Vaccinia virus
Strain: vP-5 [recombinant Vaccinia virus]
Depositors: E Paoletti
Biosafety Level:2
Shipped: frozen
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Host Organism : HeLa cells (ATCCCCL-2); CV-1 cells (ATCCCCL-70)
Effect : Yes, in vitro effects: Cytopathic effects in tissue culture
Comments : A recombinant virus consisting of an HSV-TK insert in vaccinia vTK-11. The recombinant does not express thymidine kinase. A recombinant virus consisting of an HSV-TK insert in vaccinia vTK-11. The recombinant does not express thymidine kinase. This clone does not express the inserted herpes thymidine kinase gene. [13123] A BamHI fragment coding for herpes TK was cloned into the BamHI site of the vaccinia HindIII F-fragment. This construct was then cloned into VTK-11 by in vivo recombination. [13123]
References : 13123: Paoletti E, Panicali D. Modified vaccinia virus. US Patent 4,603,112 dated Jul 29 1986 13130: Paoletti E, Panicali D. Method for immunizing animals with synthetically modified vaccinia virus. US Patent 4,722,848 dated Feb 2 1988 13139: Panicali D, et al. Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus. J. Virol. 37: 1000-1010, 1981. PubMed: 6262520
